NRIF3 is an estrogen-inducible nuclear receptor coregulator that stimulates estrogen receptor-a (ERa) transactivation functions and associates with the endogenous ER and its target gene promoter. p21-activated protein kinase 1 (Pak1) phosphorylates ERa at Ser305 and this modification is important in ERa transactivation function. Although ERa transactivation functions are regulated by co-activator activity of NRIF3, it remains unclear whether Pak1 could impact ER functions via a posttranslational modification of NRIF3. Here, we report that Pak1 phosphorylates NRIF3 at Serine28 and that NRIF3 binds to Pak1 in vitro and in vivo. We found that NRIF3 phosphorylation, co-activator activity and association with ERa increased following Pak1 phosphorylation of NRIF3's Ser28 and that activated ERa-Ser305 and NRIF3-Ser28 cooperatively support transactivation of ERa. NRIF3 expression increased significantly in cells with inducible Pak1 expression. We found that NRIF3 and ERa interaction, subcellular localization and ERa transactivation activity all increased in cells expressing the Pak1 phosphorylation-mimicking mutant NRIF3-Ser28Glu. Consistently, the NRIF3-Ser28Glu mutant exhibited an enhanced recruitment to the endogenous ER target genes and increased expression following estrogen stimulation. Finally, breast cancer cells with stable overexpression of NRIF3 showed increased proliferation and enhanced anchorage-independent growth. These findings suggest that NRIF3-Ser28 is a physiologic target of Pak1 signaling and contributes to the enhanced NRIF3 co-activator activity, leading to coordinated potentiation of ERa transactivation, its target gene expression and estrogen responsiveness of breast cancer cells.
Introduction
Co-activators are a class of proteins that interact with sequence-specific transcription factors to enhance the transcription of target genes. Recent studies have identified a number of co-activators that associate with nuclear receptors (NRs) in a ligand-dependent manner to stimulate the transactivation functions of NR. A partial list of these co-activators includes SRC-1/ NCoA-1, TIF2/GRIP1/NCoA-2, pCIP/ACTR/AIB1, the TRAP/DRIP complex (Onate et al., 1995; Kamei et al., 1996) and NRIF3, an estrogen-inducible NR co-activator (Talukder et al., 2004) . Interaction between the ligand-activated NR and these co-activators is mediated by a small a-helical motif containing the sequence LXXLL (where L denotes leucine and X is any amino acid) in the co-activator proteins. The LXXLL motif is crucial but not sufficient for the interaction with the NR, as different NRs show overlapping but distinct preferences for individual LXXLL motifs, and sequences outside this motif are also important (Freedman, 1999; Glass and Rosenfeld, 2000) .
The activities of transcription factors are also regulated by phosphorylation. The importance of phosphorylation for estrogen receptor-a (ERa) function is exemplified by growth factors such as epidermal growth factor, heregulin, insulin and the insulin-like growth factor transforming growth factor-a, as well as cyclic AMP and phorbol esters, can also activate ERa (Aronica and Katzenellenbogen, 1993; Ignar-Trowbridge et al., 1993; Ma et al., 1994; Metzger et al., 1995; Arnold et al., 1995a; Pietras et al., 1995; Bunone et al., 1996; Patrone et al., 1996) . Activated ERa, inturn, stimulates transcription of its target genes. Phosphorylation of ERa on Ser104 and/or Ser106, Ser118 and Ser167, and Tyr537 has been shown to support it transactivation function (Ali et al., 1993; Castoria et al., 1993; Le Goff et al., 1994; Arnold et al., 1994; 1995b , 1995c Joel et al., 1995) . Phosphorylation of human ERa at serine 118 is mediated by the RAS/ mitogen-activated protein kinase (MAPK) pathway (Kato et al., 1995; Bunone et al., 1996) ; activation of the MAPK pathway enables ligand-independent transactivation of human ERa by MAPK or its upstream activator (Bunone et al., 1996) . Mutation of Ser118 to Ser118-Ala, which impairs the phosphorylation on Ser118, reduces its transcription ability (Ali et al., 1993; Le Goff et al., 1994) . Similarly, p21-activated protein kinase 1 (Pak1) directly phosphorylates ERa at the N-terminal residue Ser305, and mutation of this residue to Ala (Ser305-Ala) abolishes the Pak1-mediated phosphorylation and transactivation functions of the ERa, whereas its substitution by glutamic acid (Ser305-Glu) that mimic phosphorylation promotes transactivation activity of ERa (Wang et al., 2002; Kumar and Vadlamudi, 2002; Balasenthil et al., 2004) . Intriguingly, several lines of evidence show that polypeptide factor signaling can also modulate the functional activity of NR coregulatory factors via posttranslational phosphorylation events (reviewed by Hermanson et al., 2002; Spiegelman and Heinrich, 2004; Wu et al., 2005) . For example, phosphorylation of specific members of the steroid receptor co-activator (SRC)/p160 family of proteins via different signal transduction pathways can enhance nuclear localization of SRC Wu et al., 2002) , inhibit interactions with non-NR activators (Lazaro et al., 2002) or stimulate intrinsic SRC/p160 co-activator activity (Font de Mora and Brown, 2000; Rowan et al., 2000; Wu et al., 2004) . Similarly, phosphorylation of the NR co-activator PGC-1 via p38-MAPK significantly stabilizes protein expression, leading to increased levels of co-activator activity (Pierce et al., 2001) .
Earlier studies have shown a role of NRIF3 in potentiation of transactivation functions of the NR (Li et al., 1999 (Li et al., , 2001 Talukder et al., 2004) . Further, NRIF3 itself is an estrogen-inducible gene with an ER-responsive motif in its gene promoter sequence (Talukder et al., 2004) . It was also shown that the N-terminal LXXLL (RID2) motif of NRIF3 is necessary for binding with ERa, that NRIF3 association with estrogen-responsive gene-chromatin is estrogen sensitive and that this association could be inhibited by the transcriptional corepressor MTA1. Deletion of the first 28 amino acids of NRIF3 (that contains the RID2 domain and LXXLL motif) mimics NRIF3's ERa transactivation functions (Talukder et al., 2004) . Although the deletion of the first 28 amino acids in NRIF3 impairs its binding to ERa (Talukder et al., 2004) , it remains unclear whether the impairment is due to inefficient binding or another mechanism that modifies ER-transactivation function of NRIF3 in a physiological setting. The purpose of our study was to explore the existence of mechanistic linkage between NRIF3 and ER. We found that NRIF3 is a phosphoprotein that has a consensus Pak1 phosphorylation site on Ser28 ((K/R) (R/X) (X) (S/T)) and that NRIF3 is phosphorylated on Ser28 by Pak1. We show that this phosphorylation of NRIF3 on Ser28 promotes the ability of NRIF3 to transactivate ERa by enhancing recruitment of NRIF3 to the ERa target gene chromatin, leading to enhanced anchorage-independent growth of breast cancer cells.
Results and discussion

Pak1 phosphorylates and interacts with NRIF3
To identify the potential posttranslational modifications that might affect NRIF3's co-activation of ERa, we searched the NetPhos 2.0 server (www.cbs.dtu.dk/ services/Netphos) for phosphorylation sites in NRIF3. We found several phosphorylation sites. Among these, we identified Ser28 (RKKS) as a putative Pak1 phosphorylation site ((K/R) (R/X) (X) (S/T)). Using glutathione S-transferase (GST)-purified Pak1 enzyme, we performed an in-vitro kinase assay using GST-NRIF3 and GST-NRIF3-29del (Talukder et al., 2004) . We found that Pak1 phosphorylates NRIF3 profoundly but not GST alone or the mutant NRIF3 lacking the first 28 amino acids (Figure 1a) . We next generated NRIF3 mutant wherein Ala was substituted for Ser28: Pak1 was unable to phosphorylate this mutant NRIF3 (Figure 1b) . These results indicate that Pak1 phosphorylated NRIF3 specifically at Ser28 in an in vitro system.
To identify the mechanism of NRIF3 phosphorylation in a mammalian system, we generated T7-tagged NRIF3-S28A and transfected MCF-7 cells with T7-NRIF3 or T7-NRIF3-S28A in the presence of 32 P-orthophosphoric acid and in the presence or absence of control or Pak1-specific small-interfering RNA (siRNAs). Cell lysates were immunoprecipitated with anti-T7 monoclonal antibody, resolved by SDS-polyacrylamide gel electrophoresis (PAGE), transferred to a blotting membrane and autoradiographed. The same blot was probed against either anti-Pak1 or anti-T7 antibody. As shown in Figure 1c , transiently expressed T7-NRIF3 was substantial phosphorylation in MCF-7 cells (lane 2) and such phosphorylation was inhibited in NRIF3-S28A (lane 1) or by Pak1-siRNA (lanes 3 and 4). The lower two panels in Figure 1c show that T7-NRIF3 also interacted with endogenous Pak1. Transiently expressed T7-NRIF3 in MCF-7 cells also bound with endogenous Pak1 (Figure 1d ). These findings indicate that NRIF3 is a phosphoprotein and that Pak1 interacts with and phosphorylates NRIF3 at Ser28.
NRIF3 binds with Pak1 and its expression and phosphorylation is Pak1 sensitive As Pak1 interacted with and phosphorylated NRIF3, we next explored whether NRIF3 would also interact with endogenous Pak1. Total cell lysates from MCF-7 cells were immunoprecipitated with Pak1 antibody or NRIF3 antibody and blotted with antibodies against NRIF3 or Pak1. Results showed that Pak1 weakly bound to NRIF3 (Figure 2a ) and that NRIF3 binding to Pak1 increased when the cells were stimulated with epidermal growth factor (EGF; Figure 2b ). The self-immunoprecipitation of NRIF3 was shown in Figure 2c as a control. We also examined the phosphorylation status of endogenous NRIF3. As shown in Figure 2d , endogenous NRIF3 was phosphorylated in the presence of NRIF3 promotes ER transactivation function in a Pak1-sensitive manner As Pak1 phosphorylated NRIF3 and bound to the endogenous NRIF3, we hypothesized that Pak1-mediated phosphorylation of NRIF3 influences its transactivation activity. Because NRIF3 is an estrogen-responsive gene (Talukder et al., 2004) and estrogen induced the expression of NRIF3 in an antiestrogendependent manner (Figure 3a) , we investigated whether phosphorylation of NRIF3 itself had any co-activator activity upon ER transactivation function. To determine whether Ser28 phosphorylation affects the ability of NRIF3 to co-activate the ERa transactivation function, we transfected MCF-7 cells with estrogen response element (ERE)-luc along with T7-NRIF3 or NRIF3-S28A or NRIF3-specific or control siRNA. NRIF3 proved to be a potent co-activator of ER-transactivation activity, and its co-activator function severely impaired when the Pak1 phosphorylation site in NRIF3 was inactivated (that is, NRIF3-S28A) or when endogenous NRIF3 was depleted by siRNA ( Figure 3b ). The results suggest that NRIF3 has a Ser28 phosphorylationdependent ability to co-activate ER-transactivation activity. This finding provides a new perspective to the earlier report of Pak1 phosphorylation of ERaSer305 and transactivation function (Wang et al., 2002) and raises the possibility that Pak1 phosphorylation of NRIF3 contributes to the co-activator activity of NRIF3. Consistent with this notion, NRIF3 and Pak1 costimulated ERE-transactivation, whereas Pak1 Figure 3d ) reduced the ability of NRIF3 to co-activate ERE transactivation.
NRIF3 Ser28 phosphorylation affects its interactions with ERa
We next examined the binding of ER to NRIF3 and to the phosphorylation-mimicking mutant of NRIF3 (NRIF3-Ser28 to glutamic-acid modification, ER-S305E) and an inactive mutant (ER-S305A). We found that negatively charged phosphorylation-mimicking mutant of NRIF3 bound more strongly with ERa than NIRIF3 (Figure 4a ). Likewise, negatively charged phosphorylation-mimicking mutant of ERa bound more strongly to NRIF3 than the phosphorylationinactive mutant of ERa (Figure 4b ). These findings suggest that negative charge on these serine residues 
E2
- 
ERE-luc activity promotes interaction between the two molecules. This constitutive negative charge might also promote colocalization of NRIF3 with ERa. To examine this possibility, we first determined the colocalization of T7-NRIF3 with endogenous ERa. Results in Figure 4c show that T7-NRIF3 colocalized with the endogenous ERa. We also found that endogenous NRIF3 bound strongly with endogenous ERa in an E2-sensitive manner ( Figure 4d ).
Next we determined the localization of wild-type NRIF3, NRIF3-S28A and NRIF3-S28E with ERa in MCF-7 cells. Cells were transfected as described in 'Materials and methods' section. As shown in Figure 4e , consistent weak colocalization of ERa with NRIF3 or NRIF3-S28A was seen in 54 and 55%, respectively, of the cells in dextran-coated chacoal treated (DCC) media. However, NRIF3-S28E was colocalized with ERa in 83% of transfected cells, suggesting that NRIF3 phosphorylation-mimicking modification displayed better colocalization with ERa. Together these studies suggest that the phosphorylation of NRIF3-Ser28 is involved in promoting interaction with ERa in breast cancer cells.
NRIF3-S28E and ER-S305E stimulate ER's transactivation in a cooperative manner As the interaction of phosphorylation-mimicking mutants of NRIF3 with ER was enhanced, we examined the possibility that NRIF3-S28E would further promote the transactivation function of ER-S305E. Indeed, NRIF3 promoted the transactivation activity of ER-S305E but not ER-S305A in ER-negative HeLa cells (Figure 5a) , and the contribution of NRIF3 to ERE-transactivation was much more significant with ER-S305E than with ER ( Figure 5b ). To directly delineate the possible role of Ser28 of NRIF3 on the ERE-transactivation, we coexpressed NRIF3-S28E and ER-S305E and measured ERE transactivation activity: the increase in transactivation activity was robust (Figure 5c ), suggesting that phosphorylated NRIF3 is a very strong co-activator of ER's transactivation function.
A role of Ser28 of NRIF3 in the stimulation of ER target genes Earlier we showed that NRIF3 promotes the expression of PS2 and cyclin D1 (Talukder et al., 2004) . To examine the role of NRIF3's Ser28 phosphorylation in the stimulation ER target genes such as pS2 and cyclin D1, we generated stable clones of T7-tagged vector (pcDNA), NRIF3, NRIF3-S28A and NRIF3-S28E and measured levels of pS2 and cyclin D1. We found increased levels of estrogen-inducible pS2 and cyclin D1 mRNAs in cells overexpressing NRIF3 or NRIF3-S28E but not NRIF3-S28A (Figure 6a ). The levels of cyclin D1 protein (Figure 6b ) and cyclin D1 promoter activity ( Figure 6c ) were also increased in MCF7/NRIF3 and in MCF-7/NRIF3-S28E clones. Consistent with these results, chromatin immunoprecipitation (ChIP) assays showed that NRIF3 and NRIF3-S28E (as compared to NRIF3-S28A) were effectively recruited to the promoters of pS2 and cyclin D1 in estrogenstimulated cells (Figures 6d and e) . In brief, these findings suggest that Ser28 phosphorylation of NRIF3 is important in stimulating ER-responsive genes, presumably due to increased NRIF3-ER interaction and recruitment to the target gene chromatins.
Ser28 phosphorylation of NRIF3 stimulates proliferation of breast cancer cells
To understand the significance of Ser28 phosphorylation of NRIF3 upon the biology of breast cancer cells, we next examined the effect of estrogen on the proliferation of the pooled clones of MCF-7 cells stably expressing NRIF3, NRIF3-S28A, NRIF3-S28E or pcDNA. Results indicated that overexpression of NRIF3 or NRIF3-S28E promoted the baseline as well as estrogen-induced growth of MCF-7 cells that could be further enhanced by estrogen (Figure 7a ), implicating NRIF3-Ser28 in the estrogen-responsiveness of breast cancer cells. Consistent with these results, expression of NRIF3 or NRIF3-S28E but not NRIF3-S28A promoted both basal and estrogen-inducible growth of MCF-7 in an anchorage-independent manner (Figure 7b ). In brief, Ser28 phosphorylation of NRIF3 leads to cellular consequences. Collectively, the results presented here provide novel insights into NRIF3 function, leading to recognition of its phosphorylationdependent co-activator activity upon ERa transcriptional action, and consequently, growth stimulation of breast cancer cells.
In summary, results presented here have identified serine 28 (RKKS) of NRIF3 as a Pak1 phosphorylation site. In addition, we found that NRIF3 but not its Ser28-phosphorylation mutant confers co-activator function upon ER target genes. Phosphorylation of coactivators modifies 3D conformation of coregulators in favor of a stabilized co-activator, leading to increased co-activator activity. Consistent with this notion, NRIF3-Ser28 phosphorylation potentiated ERa transactivation function, presumably due to an enhanced NRIF3-ERa interaction and its resulting recruitment to the ER target gene chromatin. As Pak1 signaling is known to phosphorylate ERa on Ser305 and we have now established that Pak1 also phosphorylates NRIF3-Ser28, we also established a positive cooperative role of NRIF3-Ser28 and ERa-Ser305 in stimulating ER transactivation function (Figure 7c ) and expression of the target genes pS2 and cyclin D1. Our results implicated activated NRIF3 (that is, NRIF3-S28E) in the ER-induced stimulation of proliferation and anchorage-independent growth in breast cancer cells, thus demonstrating the functional significance of these molecular interactions in growth stimulation of breast cancer cells.
Materials and methods
Cell culture and antibodies
Human breast cancer cells were cultured in Dulbecco's modified Eagle's medium (DMEM)/F12 medium supplemented with 10% fetal bovine serum (FBS). For estrogen treatment, regular medium was replaced by medium containing 3% DCC (charcoal-stripped serum). Antibody against NRIF3 (catalog no. 10743-1-AP) was purchased from Proteintech Group Inc. (Chicago, IL, USA); anti-T7-tag (catalog no. 69522) from EMD Chemicals Inc. (San Diego, CA, USA); anti-HA-tag (catalog no. sc-7392), anti-ERa (catalog no. sc-7207) and anti-cyclin D1 from the Santa Cruz Biotechnology (Santa Cruz, CA, USA); antiactin (catalog no. a-4700) and anti-vinculin (catalog no. v-9131) from Sigma-Aldrich (St Louis, MO, USA); anti-Pak1 (catalog no. 2602) from Cell Signaling Technology (Boston, MA, USA). Anti-mouse and anti-rabbit horseradish peroxidase conjugates were purchased from Amersham (Piscataway, NJ, USA).
Pak1 kinase assay
In-vitro kinase assays using GST-NRIF3 fusion protein were performed in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer (50 mM HEPES, 10 mM MgCl 2 , 2 mM MnCl 2 , 1 mM DTT) containing 1 mg of purified bacterially expressed GST-Pak1 enzyme, 10 mCi of [g-32 P]ATP, and 25 mM unlabeled ATP. The reaction was carried out in a 30 ml volume for 30 min at 30 1C and then stopped by addition of 10 ml of 4 Â SDS buffer. Reaction products were then analysed on an SDS-PAGE, transferred to a blot and developed by autoradiography.
Plasmid construction and point mutations at Ser28 of NRIF3
A PCR-based approach was used for site-directed mutagenesis of the putative Pak1 phosphorylation site at Ser28 of full-length GST-NRIF3. We used the following primers: for Ser28Ala, the forward primer was 5 0 -AGGAAGAAAGC TGTTATAACTTAT-3 0 and the reverse primer was 5 0 -ATAA GTTATAACAGCTTTCTTCCT-3 0 ; for Ser28Glu, the forward primer was 5 0 -AGGAAGAAAGAGGTTATAACT TAT-3 0 and the reverse primer was 5 0 -ATAAGTTATAAC CTCTTTCTTCCT-3 0 using Stratagene's Quick Change sitedirected mutagenesis kit. To make T7-tagged S28A and S28E-mutated full-length NRIF3 for mammalian expression, we digested the GST constructs with BamHI and NotI and ligated them into pcDNA3.1A (Invitrogen, Carlsbad, CA, USA) at the same sites.
In-vitro transcription, translation and GST pulldown assays
In-vitro transcription and translation of the test proteins were performed using the TNT Transcription-Translation System (Promega, Madison, WI, USA). T7-tagged plasmid DNA (1 mg) was translated in the presence of 35 S-labeled methionine in a 50-ml reaction volume by using the T7-TNT reaction mixture. The reaction mixture was diluted to 1 ml with the NP40 lysis buffer, and an aliquot (250 ml) was used for each GST pulldown assay. The identity of the translated reaction mixture was verified by subjecting 2 ml to SDS-PAGE and autoradiography. The GST pulldown assays were performed by incubating equal amounts of GST or GST fusion protein immobilized to glutathione-Sepharose beads (Amersham) with in-vitro translated 35 S-labeled test protein. The mixtures were incubated for 2 h at 4 1C and washed six times with NP40 lysis buffer. Bound proteins were eluted with 2 Â SDS buffer, separated by SDS-PAGE and visualized by autoradiography. The transferred protein on the blot was visualized using Ponceau S stain.
Interference of NRIF3 and Pak1 expression by siRNA We used siRNA designed by Qiagen (Valencia, CA, USA) to target human NRIF3 (Talukder et al., 2004) . Human Pak1 siRNA was bought from Cell Signaling (Beverly, MA, USA). As a control, we used a commercially available nonspecific random siRNA. MCF-7 cells were seeded at 30% density the day before transfection in six-well plates. On the day of transfection, cells were changed to antibiotic-free 10% serum or 3% DCC medium (for estrogen treatment). siRNA transfections were performed by using oligofectamin reagent (Invitrogen) according to the manufacturer's instructions with 12 ml of 20 mM siRNA and 4 ml of oligofectamin reagent per well in six-well plates (50 nM final concentration). For estrogen treatment, cells were transfected with siRNA in 3% DCC serum. For luciferase assay, cells were re-transfected after 24 h of siRNA transfection with ERE-luciferase plus other plasmids and incubated in 3% DCC medium for another 48 h; estrogen (10 À9 M) was added during the last 8 h before harvest.
Transient transfection, immunoprecipitation, in-vivo phosphorylation and western blot MCF-7 cells at 70% confluence in 60-mm plates were transiently transfected with 4 mg of T7-tagged wtNRIF3 or S28A-NRIF3 using Fugene method (Roche Biochemical, NJ, USA). Some plates were also transfected with Pak1 siRNA (50 nM final concentration) 24 h before plasmid transfection. For in-vivo phosphorylation, cells were washed with phosphate-free medium containing 1 Â Na-pyruvate, 1 Â L-glutamine and 2% dialysed fetal calf serum (FCS) and incubated for 1 h in the same medium. Then 32 P-labeled orthophosphate (20 ml/ml; specific activity, 20 mCi/ml) was added and incubated overnight at 37 1C. Cells were washed with 1 Â phosphatebuffered saline (PBS) and lysed in Triton X-100 lysis buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 1.5 mM MgCl 2 , 1 mM ethylene glycol tetraacetic acid, 1 mM DTT, 1% Triton X-100, 10% glycerol containing 1 mM NaVO5, protease inhibitor cocktail (Roche Biochemical) for 15 min on ice and immunoprecipitated with monoclonal anti-T7-agarose beads or NRIF3 antibody for 4 h at 4 1C, washed three times with washing buffer, boiled for 5 min in 2 Â SDS-loading buffer and run into 12% SDS-PAGE, and finally transferred to nitrocellulose blot overnight at 4 1C. For in-vivo phosphorylation, the blot was developed by autoradiogram, and for western blot the same membrane was blocked with 5% fat-free milk and developed against monoclonal T7 antibody or anti-Pak1 antibody using enhanced chemiluminescence method.
Stable cell lines MCF-7 cells were transfected with three different plasmids of T7-NRIF3 constructs (wtNRIF3, S28A-NRIF3 and S28E-NRIF3). After 48 h, G418 (500 mg/ml final concentration) was added and selection pressure maintained for 3 weeks. Clones from each plate were pooled and maintained as individual clones. Total RNA was isolated from cell lines stably transfected with pcDNA and NRIF3 using Trizol (Life Technologies Inc., Rockville, MD, USA). Expression of T7-NRIF3 was verified by reverse transcription (RT)-PCR using T7-tagged forward primer is pcDNA982For 5 0 -CAGCAAA TGGGTCGGGATC-3 0 and the reverse primer was NRIF3-373Rev 5 0 -GCTCTCTACTGCCCTCCAAA-3 0 and western blot using anti-T7 monoclonal antibody (mAb) and NRIF3 antibody (PTG Inc., Chicago, IL, USA).
Immunofluorescent labeling and confocal microscopy Indirect immunofluorescence was used to establish the cellular localization of the T7 tag of transfected wild-type NRIF3 and 
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- endogenous ERa. Briefly, MCF-7 cells were plated on sterile glass coverslips in six-well plates and allowed to attach overnight. Cells were then co-transfected with wild-type T7-NRIF3. After 24 h, cells were rinsed twice in PBS, fixed in 4% phosphate-buffered paraformaldehyde for 15 min and permeabilized in acetone at À20 1C for 4 min. Cells were then blocked in 5% normal goat serum-PBS for 30 min, incubated with primary antibodies raised against T7 (Bethyl; Montgomery, TX, USA) or ERa (sc-7207; Santa Cruz Biotechnology) diluted 1:1000 and 1:100, respectively, in 1% NGS-PBS for 1 h at room temperature. Following incubation, cells were washed three times in PBS and then incubated with goat antimouse or goat anti-rabbit secondary antibodies conjugated with 546-Alexa (red) or 488-Alexa (green) from Molecular Probes (Eugene, OR, USA). The DNA dye TO-PRO-3 (Molecular Probes) was used for nuclear localization (blue). Microscopic analyses were performed using an Olympus FV300 laser scanning confocal microscope in accordance with established methods, utilizing sequential laser excitation to minimize the possibility of fluorescence emission bleed through. Each image consisted of a single Z section captured at the same cellular level and magnification.
For the effect of estrogen on localization of NRIF3, MCF-7 cells were transfected with either wild-type or mutant T7-NRIF3. After 24 h, cells were incubated in DCC media without serum for 48 h then treated with 10% FCS with and without pretreatment with the pure antiestrogen ICI 182 780 (ICI) (10 À8 M for 60 min), or with 17b-estradiol (10 À7 M for 30 min). Following treatment, cells were fixed and stained with primary antibodies raised against T7 (Novegen, Madison, WI, USA) or ERa. Cells demonstrating nuclear colocalization (yellow) of transfected NRIF3 (green) and endogenous ERa (red) in at least 150 cells per treatment group were counted and graphed as a percentage of the total cells counted.
Transient transfection and promoter assays
Cells were maintained in DMEM/F12 (1:1) supplemented with 10% FCS. For reporter-gene transient transfections, cells were cultured in medium without phenol red and containing 3% charcoal-stripped (DCC) serum for 24-36 h. Transient transfection with the appropriate plasmids was performed using Fugene-6 (Roche Biochemical) according to the manufacturer's instructions, and promoter assays were performed 48 h after transfection.
Chromatin immunoprecipitation assay T7-NRIF3 stable clones and pcDNA control vector were used for the ChIP assay. The cells were kept in a medium without phenol red and containing 3% charcoal-stripped (DCC) serum 48 h before estrogen or ICI treatment or both; when both were used, ICI was added 1 h before estrogen. ChIP assay was performed as described (Talukder et al., 2004) ). Approximately 1 Â 10 6 cells were treated with 1% formaldehyde (final concentration, v/v) for 10 min at 37 1C to cross-link histones to DNA and washed twice with PBS containing protease inhibitor cocktail. Cells were lysed by sonication and immunoprecipitated with T7 mAb (Novagen). The immunoprecipitates were washed, and the DNA was eluted off the beads; purified DNA (phenol-chloroform extraction) was subjected to PCR. The sequence of the forward and reverse primers for pS2 promoter used in this study was 5 0 -GAATTAGCTTAGGCCTAGACGGAATG-3 0 and 5 0 -AG GATTTGCTGATAGACAGAGACGAC-3 0 , respectively. 17-b-Estradiol, ICI-182780 and stock chemicals were obtained from Sigma. The sequences of the forward and reverse primers for NRIF3 promoter were 5 0 -ACTACCTTTCTCAGCCTCT GGTAACC-3 0 (spanning region À5193 to À5218 bp) and 5 0 -GGGAACCCTCTTACACTGTTGGTAG-3 0 (spanning region À4730 to À755 bp), respectively.
MTT cell viability assay
The cell viability assay is based on the ability of viable mitochondria to convert 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), a soluble tetrazolium salt, into an insoluble formazan precipitate, which can be quantitated by spectrophotometry. NRIF3 and pcDNA clones were seeded in a 96-well plate (2000 cells per plate). After 24 h, white medium containing 3% DCC was exchanged for regular medium. At 72 h, cells were treated with or without estrogen for 15 h. Then cells were rinsed with 1 Â PBS and 0.1 ml MTT solution (5 mg/ml in PBS) was added. Cells were incubated at 37 1C for cleavage of MTT for 4 h (at the end of this time, the MTT formazan produced in wells containing live cells appears as black, fuzzy crystals on the bottom of the well) and 0.1 ml isopropanol/HCl (0.4 N) was added to each well and mixed thoroughly by repeated pipetting with a multichannel pipettor (isopropanol dissolves the formazan to give a homogeneous blue solution suitable for absorbance measurement). The absorbance was measured within an hour on an enzymelinked immunosorbent assay plate reader at 570 nm.
Cell growth and soft agar assays Colony growth assays were performed as described previously (Vadlamudi et al., 2000) . Briefly, a 1 ml of solution of 0.6% Difco agar in DMEM supplemented with 10% FBS with insulin was layered onto 35 Â 15 mm graded tissue culture plates. Stable clones of pcDNA and NRIF3 (10 000 cells per plate) were mixed with 1 ml of 0.36% Bactoagar solution in DMEM prepared in a similar manner and layered on top of the 0.6% Bactoagar layer. Plates were incubated for 28 days. For treatment with estrogen, cells were replaced with DCC serum and then added 10 À9 M estrogen.
Reproducibility
All the data are the mean value of three independent experiments.
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